Mielóma multiplex: vizsgálatok itt: Belgium
30 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
- Where
- Antwerp, Roeselare
- Életkor
- 18 év and over
- People
- 410 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT05730036 · EU 2022-501396-62-00 - 3. fázisTaking peopleA Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
- Where
- Antwerp, Brugge, Genk, Jette, Liège, Yvoir
- Életkor
- 18 év and over
- People
- 915 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT07222761 · EU 2024-519504-27-00 - 2. fázisTaking peopleA Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- Where
- Edegem, Leuven, Liège, Sint-Lambrechts-Woluwe
- Életkor
- 18 év and over
- People
- 510 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT04634552 · EU 2023-504581-29-00 - 4. fázisTaking peopleA Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Where
- Edegem, Gent, Leuven
- Életkor
- 18 év and over
- People
- 295 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05201781 · EU 2023-505530-10-00 - 3. fázisTaking peopleA Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Where
- Anderlecht, Antwerp, Gent, Kortrijk, Leuven
- Életkor
- 18 év and over
- People
- 1590 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05552222 · EU 2023-503442-30-00 - 1. fázisTaking peopleA Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
- Where
- Edegem, Gent, Liège
- Életkor
- 18 év and over
- People
- 180 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05652335 · EU 2023-503679-12-00 - 3. fázisTaking peopleA Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- Where
- Antwerp, Genk, Ghent, Sint-Niklaas
- Életkor
- 18 év and over
- People
- 810 worldwide
- Run by
- Celgene
See details and how to joinNCT05519085 - 3. fázisTaking peopleA Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- Where
- Edegem, Gent, Sint-Lambrechts-Woluwe, Yvoir
- Életkor
- 18 év and over
- People
- 440 worldwide
- Run by
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT06615479 · EU 2024-515279-37-00 - 3. fázisTaking peopleA Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- Where
- Brugge, Charleroi, Gent, Jette, Ottignies-Louvain-la-Neuve, Roeselare, Yvoir
- Életkor
- 18 év and over
- People
- 1060 worldwide
- Run by
- Pfizer
See details and how to joinNCT05623020 · EU 2024-514139-50-00 - 1/2. fázisTaking peopleA Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
- Where
- Gent, Leuven, Liège
- Életkor
- 18 év and over
- People
- 325 worldwide
- Run by
- AbbVie
See details and how to joinNCT06953960 · EU 2024-517140-65-00 - 1/2. fázisTaking peoplePhase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
- Where
- Antwerp, Brussels
- Életkor
- 18 év and over
- People
- 387 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT03761108 · EU 2024-511454-45-00 - 3. fázisTaking peopleSingle-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Where
- Edegem, Ghent, Liège, Roeselare
- Életkor
- 18 év and over
- People
- 63 worldwide
- Run by
- CSL Behring
See details and how to joinNCT07648264 · EU 2026-525626-38-00 - 3. fázisTaking peopleElranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients
- Where
- Anderlecht, Charleroi, Liège, Sint-Lambrechts-Woluwe, Yvoir
- Életkor
- 18 év to 69 év
- People
- 824 worldwide
- Run by
- Intergroupe Francophone du Myelome
See details and how to joinNCT06918002 · EU 2024-516418-39-00 - No phaseTaking peopleStudy on the Clinical Efficacy of Teclistamab and Talquetamab
- Where
- Bonheiden, Brussels, Charleroi, Edegem, Ghent, Hasselt, Hornu, Kortrijk, Leuven, Liège, Mons, Roeselare, Sint-Niklaas, Yvoir
- Életkor
- 18 év and over
- People
- 100
- Run by
- Universitaire Ziekenhuizen KU Leuven
See details and how to joinNCT06477783 - 3. fázisTaking peopleA long-term follow-up study for patients treated with Galapagos CAR T cell therapies
- Where
- Edegem, Leuven, Liège, Roeselare, Sint-Lambrechts-Woluwe
- Életkor
- 18 év and over
- People
- 309 worldwide
- Run by
- Lakefront Biotherapeutics
See details and how to join2023-510173-34-00 · EU 2023-510173-34-00 - 1/2. fázisTaking people[68Ga]Ga-PentixaFor positron emission tomography for improved risk and disease assessment in myeloma
- Where
- Edegem, Gent, Leuven
- Életkor
- 18 év and over
- People
- 90 worldwide
- Run by
- University Of Antwerp
See details and how to join2022-501811-14-00 · EU 2022-501811-14-00 - 1. fázisTaking peopleA study to evaluate the Safety, Pharmacokinetics, and Activity of Subcutaneous Cevostamab (BFCR4350A) in Patients with Relapsed or Refractory Multiple Myeloma (CAMMA 3)
- Where
- Gent, Jette
- Életkor
- 18 év and over
- People
- 45 worldwide
- Run by
- Genentech Inc.
See details and how to join2023-503404-89-00 · EU 2023-503404-89-00 - 3. fázisTaking peopleA Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- Where
- Charleroi, Yvoir
- Életkor
- 18 év and over
- People
- 893 worldwide
- Run by
- Pfizer
See details and how to joinNCT05020236 · EU 2023-509208-14-00 - 3. fázisTaking peopleMagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Where
- Boussu, Charleroi, Gent, Jette, Ottignies-Louvain-la-Neuve, Roeselare, Verviers, Yvoir
- Életkor
- 18 év and over
- People
- 492 worldwide
- Run by
- Pfizer
See details and how to joinNCT06152575 · EU 2023-507871-23-00 - 1/2. fázisTaking peopleA Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax (ABBV-453) Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
- Where
- Gent, Leuven, Liège
- Életkor
- 18 év and over
- People
- 88 worldwide
- Run by
- AbbVie Deutschland GmbH & Co. KG
See details and how to join2025-525105-20-00 · EU 2025-525105-20-00 - 2. fázisTaking peopleA Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
- Where
- Antwerp, Brasschaat, Brugge, Herentals, Mechelen, Roeselare
- Életkor
- 18 év and over
- People
- 116 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT06140524 · EU 2023-505242-25-00 - No phaseTaking peopleImmune Fitness in Older Patients With Relapsed and Refractory Multiple Myeloma
- Where
- Anderlecht, Brussels, Woluwe-Saint-Lambert
- Életkor
- 65 év and over
- People
- 31
- Run by
- Jules Bordet Institute
See details and how to joinNCT07674498 - No phaseTaking people"Pseudo-scanner" MRI Sequences for the Detection of Bone Lesions in Multiple Myeloma
- Where
- Brussels
- Életkor
- 18 év and over
- People
- 45
- Run by
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
See details and how to joinNCT06988020 - 3. fázisTaking peopleA Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- Where
- Roeselare
- Életkor
- 18 év and over
- People
- 520 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT06679101 · EU 2024-516030-35-00 - 3. fázisTaking peopleA Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
- Where
- Antwerp, La Louvière, Leuven
- Életkor
- 18 év and over
- People
- 1000 worldwide
- Run by
- European Myeloma Network B.V.
See details and how to joinNCT06932562 · EU 2024-519827-16-00